Opportunity Information: Apply for PAR 21 022
The funding opportunity titled "Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)" (PAR-21-022) is a National Institutes of Health (NIH) research grant announcement released under the Collaborative Research on Addiction at NIH (CRAN) initiative. It is jointly issued by three NIH institutes: the National Institute on Drug Abuse (NIDA), the National Institute on Alcohol Abuse and Alcoholism (NIAAA), and the National Cancer Institute (NCI). The central aim is to fund multi-site research that develops and rigorously tests interventions, models, and/or implementation frameworks that operate at the system level, meaning they target how organizations and service systems deliver substance use prevention and treatment rather than focusing only on individual-level clinical outcomes.
The research focus is specifically on system-level implementation of evidence-based interventions, guidelines, or principles intended to improve the delivery and real-world performance of substance use prevention and treatment services. In practice, this means proposals are expected to address problems like low adoption of proven practices, inconsistent quality of care across settings, weak coordination between sectors, limited reach to underserved populations, and poor long-term sustainability after initial implementation support ends. Projects supported under this announcement are meant to generate evidence about how to increase uptake, strengthen fidelity and quality, improve service delivery workflows, and ensure practices can be maintained over time across multiple sites. The "clinical trial optional" designation indicates that applicants may propose studies that do or do not meet NIH’s definition of a clinical trial, depending on the research questions and methods.
This opportunity uses the NIH R01 mechanism, which is a standard research project grant designed for substantial, hypothesis-driven or programmatic studies. The announcement lists an award ceiling of $500,000, signaling the maximum amount expected per award under the terms provided in the source information. The opportunity is categorized as discretionary funding and aligns with the health and education activity areas, with CFDA numbers 93.273, 93.279, and 93.399, reflecting the participating NIH program areas tied to drug abuse, alcohol abuse, and related research portfolios.
A wide range of U.S.-based organizations are eligible to apply. Eligible applicants include state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations other than federally recognized tribal governments; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (as long as they are not institutions of higher education in that category); for-profit organizations other than small businesses; small businesses; and other qualifying entities. The announcement also explicitly highlights additional eligible applicant types, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISI), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, Indian/Native American tribal governments that are not federally recognized, and U.S. territories or possessions.
There are strict limits on foreign involvement. Non-domestic (non-U.S.) entities are not eligible to apply, and non-domestic components of U.S. organizations are not eligible. In addition, foreign components, as defined by the NIH Grants Policy Statement, are not allowed under this funding opportunity, which effectively confines the supported work to domestic U.S. settings and activities.
Key administrative details from the source include an original closing date of November 15, 2021, and a creation date of November 16, 2020. The funding opportunity is administered by NIH, and while the source excerpt does not specify the expected number of awards, it clearly frames the program’s intent: to support multi-site studies that produce actionable, generalizable evidence about how health, behavioral health, community, and related service systems can more effectively implement and sustain evidence-based substance use prevention and treatment approaches at scale.Apply for PAR 21 022
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273, 93.279, 93.399.
- This funding opportunity was created on 2020-11-16.
- Applicants must submit their applications by 2021-11-15. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $500,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Education, Health
Next opportunity: Materials and Chemical Sciences Research for Quantum Information Science
Previous opportunity: Strengthening the Rule of Law in Ukraine by Providing Soft Skills Training for Prosecutors and Defense Attorneys
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 21 022
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 21 022) also looked into and applied for these:
| Funding Opportunity |
|---|
| Strengthening HIV Prevention Efforts for Women in the Southern U.S. (R34 Clinical Trial Optional) Apply for RFA MH 21 150 Funding Number: RFA MH 21 150 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Strengthening HIV Prevention Efforts for Women in the Southern U.S. (R01 Clinical Trial Optional) Apply for RFA MH 21 151 Funding Number: RFA MH 21 151 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed) Apply for PAR 21 065 Funding Number: PAR 21 065 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) Apply for PAR 21 066 Funding Number: PAR 21 066 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) Apply for PAR 21 067 Funding Number: PAR 21 067 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed) Apply for RFA CA 21 003 Funding Number: RFA CA 21 003 Agency: National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trial Not Allowed) Apply for RFA CA 21 005 Funding Number: RFA CA 21 005 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 21 004 Funding Number: RFA CA 21 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 21 006 Funding Number: RFA CA 21 006 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U54 Clinical Trial Optional) Apply for RFA CA 21 009 Funding Number: RFA CA 21 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) Apply for RFA CA 21 008 Funding Number: RFA CA 21 008 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) Apply for RFA CA 21 012 Funding Number: RFA CA 21 012 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) Apply for RFA CA 21 007 Funding Number: RFA CA 21 007 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) Apply for RFA CA 21 011 Funding Number: RFA CA 21 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U2C Clinical Trial Optional) Apply for RFA CA 21 010 Funding Number: RFA CA 21 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed) Apply for RFA CA 21 001 Funding Number: RFA CA 21 001 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) Apply for RFA CA 21 014 Funding Number: RFA CA 21 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Cellular Cancer Biology Imaging Research (CCBIR) Program (U54, Clinical Trial Not Allowed) Apply for RFA CA 21 002 Funding Number: RFA CA 21 002 Agency: National Institutes of Health Category: Education, Health Funding Amount: $1,250,000 |
| Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R41/R42 Clinical Trial Optional) Apply for RFA DA 21 031 Funding Number: RFA DA 21 031 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD) (R43/R44 Clinical Trial Optional) Apply for RFA DA 21 032 Funding Number: RFA DA 21 032 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 21 022", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
